The Society for Immunotherapy of Cancer (SITC)’s latest manuscript, “Society for Immunotherapy of Cancer recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease” is now available in the Journal for ImmunoTherapy of Cancer.
Dive into expert guidance on trial optimization to better demonstrate efficacy of intratumoral immunotherapies. Find guidance on a variety of design elements including:
- Patient stratification factors
- Exclusion criteria
- Study arm considerations
- Optimal endpoints
- Response assessments
- Patient populations to prioritize
View manuscript: https://lnkd.in/gDfBw-3N
Thank you to the members of the Intratumoral Immunotherapy Clinical Trials Expert Panel, Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Diwakar Davar, MD, MS, UPMC Hillman Cancer Center, Aurélien Marabelle, MD, PhD, Gustave Roussy, Robert Andtbacka, MD, CM, FACS, FRCSC, HiFiBiO Therapeutics, Bhardwaj Nina, MD, PhD, The Icahn School of Medicine at Mount Sinai, Joshua Brody, MD, The Icahn School of Medicine at Mount Sinai, Jason Chesney, MD, PhD, University of Louisville, Robert Coffin, PhD, Replimune, Thierry de Baere, MD, PhD, Gustave Roussy, Tanja de Gruijl, PhD, Amsterdam University Medical Centers, Matthew Fury, MD, Regeneron Pharmaceuticals, Inc., Greg Goldmacher, MD, PhD, MBA, Merck, Kevin J. Harrington, BSc, MBBS, MRCP, FRCR, FRCP, PhD, DIC, The Royal Marsden - Private Care, Howard Kaufman, MD, Ankyra Therapeutics, Ciara M. Kelly, Memorial Sloan Kettering Cancer Center, Anuradha D Khilnani, MD, Merck, Ke Liu , MD, PhD, Marengo Therapeutics, Sherene Loi, MD, PhD, Peter MacCallum Cancer Centre, Georgina V. Long, MBBS, PhD, BSc, FRAC, University of Sydney
Ignacio Melero, MD, PhD, University of Navarra, Mark Middleton, MD, PhD, University of Oxford, Bart Neyns, MD, PhD, Universitair Ziekenhuis Brussel
David James Pinato, MD, MRes, PhD, Imperial College London
Rahul A. Sheth, MD, The University of Texas MD Anderson Cancer Center
Stephen Solomon, MD, Memorial Sloan Kettering Cancer Center and Philippe Szapary MD, MSCE, Johnson & Johnson.
